NASDAQ:FOLD • US03152W1099
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for AMICUS THERAPEUTICS INC (FOLD).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-01-22 | Jefferies | Downgrade | Buy -> Hold |
| 2025-12-29 | Leerink Partners | Downgrade | Outperform -> Market Perform |
| 2025-12-22 | Citigroup | Downgrade | Buy -> Neutral |
| 2025-12-19 | Cantor Fitzgerald | Downgrade | Overweight -> Neutral |
| 2025-12-19 | Needham | Downgrade | Buy -> Hold |
| 2025-12-17 | Citigroup | Initiate | Buy |
| 2025-11-06 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-11-05 | Goldman Sachs | Maintains | Neutral -> Neutral |
| 2025-09-18 | Needham | Upgrade | Hold -> Buy |
| 2025-07-17 | Morgan Stanley | Upgrade | Equal-Weight -> Overweight |
| 2025-05-02 | UBS | Maintains | Buy -> Buy |
| 2025-05-02 | Goldman Sachs | Maintains | Neutral -> Neutral |
| 2025-02-20 | Needham | Reiterate | Hold -> Hold |
| 2025-02-20 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-01-15 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2025-01-13 | Needham | Reiterate | Hold -> Hold |
| 2024-12-13 | Morgan Stanley | Downgrade | Overweight -> Equal-Weight |
| 2024-11-12 | JP Morgan | Maintains | Overweight -> Overweight |
| 2024-11-07 | Cantor Fitzgerald | Maintains | Overweight -> Overweight |
| 2024-11-07 | Guggenheim | Maintains | Buy -> Buy |
| 2024-11-07 | Needham | Reiterate | Hold |
| 2024-10-17 | B of A Securities | Maintains | Buy -> Buy |
| 2024-10-11 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2024-09-20 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2024-09-06 | Jefferies | Initiate | Buy |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 399.356M 21.31% | 528.295M 32.29% | 634.21M 20.05% | 764.22M 20.50% | 906.32M 18.59% | 1.09B 20.27% | 1.29B 18.35% | 1.482B 14.88% | 1.734B 17.00% | 1.814B 4.61% | 1.9B 4.74% | |
| EBITDA YoY % growth | -68.204M 65.93% | 42.611M 162.48% | 41.951M -1.55% | 159.51M 280.23% | 263.52M 65.21% | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -76.077M 62.98% | 34.064M 144.78% | 34.491M 1.25% | 148.42M 330.32% | 251.28M 69.30% | 389.19M 54.88% | 548.14M 40.84% | 709.02M 29.35% | 983.99M 38.78% | 1.055B 7.22% | 1.131B 7.20% | |
| Operating Margin | -19.05% | 6.45% | 5.44% | 19.42% | 27.73% | 35.71% | 42.49% | 47.84% | 56.75% | 58.16% | 59.53% | |
| EPS YoY % growth | -0.51 37.80% | -0.18 64.71% | -0.08 58.33% | 0.34 555.10% | 0.68 97.79% | 0.89 31.95% | 2.12 138.17% | 2.76 30.29% | 3.53 27.68% | 3.75 6.36% | 4.00 6.52% |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | |
|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | 0.03 146.21% | 0.08 217.82% | 0.09 58.10% | 0.11 2,144.00% | 0.22 593.79% | 0.24 196.81% | 0.28 190.32% |
| Revenue Q2Q % growth | 165.25M 31.94% | 185.81M 20.12% | 198.16M 17.21% | 211.86M 14.39% | 201.96M 22.21% | 233.58M 25.71% | 221.34M 11.70% |
| EBITDA Q2Q % growth | 12.839M 309.96% | 42.306M 1,136.15% | 53.043M 33.17% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | 18.922M 337.95% | 35.243M 553.46% | 41.018M 19.69% | 48.229M 202.45% | N/A | N/A | N/A |
All data in USD
14 analysts have analysed FOLD and the average price target is 15.81 USD. This implies a price increase of 9.72% is expected in the next year compared to the current price of 14.41.
AMICUS THERAPEUTICS INC (FOLD) will report earnings on 2026-04-29.
The consensus EPS estimate for the next earnings of AMICUS THERAPEUTICS INC (FOLD) is 0.03 USD and the consensus revenue estimate is 165.25M USD.
The expected long term growth rate for AMICUS THERAPEUTICS INC (FOLD) is 19.24%.